Hye Ryeon Kim

559 total citations
19 papers, 449 citations indexed

About

Hye Ryeon Kim is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hye Ryeon Kim has authored 19 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hye Ryeon Kim's work include Peptidase Inhibition and Analysis (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Hye Ryeon Kim is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Hye Ryeon Kim collaborates with scholars based in South Korea. Hye Ryeon Kim's co-authors include Won Mook Choi, Tran Van Tam, Nguyễn Bảo Trung, Jin Suk Chung, Seung Hyun Hur, Eui Jung Kim, Tae-Ung Yoon, Chang Yeon Lee, Seung-Ik Kim and Jihyun An and has published in prestigious journals such as Journal of Clinical Oncology, Chemical Engineering Journal and Sensors and Actuators B Chemical.

In The Last Decade

Hye Ryeon Kim

18 papers receiving 443 citations

Peers

Hye Ryeon Kim

EEE

EOMM

Jieyi Ye China

Zicheng Li China

Xiaoyuan Liang China

Bowen Zhuang China

Huimin Liu China

Ruiqin Wang China

Sitong Guo China

Weixia Wang China

Xueping Cao China

Jieyi Ye China

Hye Ryeon Kim

90 ×0.4

104 ×1.0

EEE

41 ×0.4

EOMM

111 ×1.2

39 ×0.6

Citations per year, relative to Hye Ryeon Kim Hye Ryeon Kim (= 1×) peers Jieyi Ye

Countries citing papers authored by Hye Ryeon Kim

Since Specialization

Citations

This map shows the geographic impact of Hye Ryeon Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hye Ryeon Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hye Ryeon Kim more than expected).

Fields of papers citing papers by Hye Ryeon Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hye Ryeon Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hye Ryeon Kim. The network helps show where Hye Ryeon Kim may publish in the future.

Co-authorship network of co-authors of Hye Ryeon Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Hye Ryeon Kim. A scholar is included among the top collaborators of Hye Ryeon Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hye Ryeon Kim. Hye Ryeon Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kim, Hye Ryeon, et al.. (2024). Relationship between METS-IR and thyroid cancer incidence in Korea: a nationwide population-based study. Frontiers in Oncology. 14. 1383864–1383864. 3 indexed citations

Kim, Hye Ryeon, Jeong Eun Kim, Hyojeong Kim, et al.. (2024). Phase II trial, multicenter, first line paclitaxel-avelumab treatment for inoperable angiosarcoma.. Journal of Clinical Oncology. 42(16_suppl). 11512–11512. 4 indexed citations

Kim, Hye Ryeon, Su Jin Lee, Mi Sun Ahn, et al.. (2023). Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial). Journal of Cancer Research and Therapeutics. 20(3). 972–978.

Kim, Hye Ryeon, Sang Eun Yoon, Darae Kim, et al.. (2022). Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea. Clinical Lymphoma Myeloma & Leukemia. 23(2). 97–103. 1 indexed citations

Kim, Hye Ryeon, Jung Hun Kang, Sung Hyun Kim, et al.. (2022). Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. Cancers. 14(14). 3440–3440. 1 indexed citations

Jo, Hyunji, Seri Park, Hye Ryeon Kim, et al.. (2022). Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort. Cancers. 14(19). 4839–4839. 6 indexed citations

Jo, Hyunji, Joo-Hyun Hong, Hong-Sik Kim, et al.. (2022). A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. Frontiers in Oncology. 12. 874385–874385. 1 indexed citations

Kim, Hong-Sik, Ryul Kim, Hye Ryeon Kim, et al.. (2022). HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology. 12. 834104–834104. 21 indexed citations

Lee, Ji Hyun, Sung‐Hyun Kim, Hye Ryeon Kim, et al.. (2022). Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma. International Journal of Hematology. 117(2). 225–235. 4 indexed citations

10.

Kim, Hye Ryeon, Hyunji Jo, Hong-Sik Kim, et al.. (2022). Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. Cancer Research and Treatment. 55(1). 344–349. 4 indexed citations

11.

Kim, Hong-Sik, Ryul Kim, Hyunji Jo, et al.. (2022). Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer. Therapeutic Advances in Gastroenterology. 15. 1098300614–1098300614. 5 indexed citations

12.

Kim, Hana, Hyo Jung Kim, Hong-Sik Kim, et al.. (2021). Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. Cancers. 13(22). 5835–5835. 9 indexed citations

13.

Kim, Hye Ryeon, Su Jin Lee, Sehhoon Park, et al.. (2021). A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer. Cancer Research and Treatment. 54(3). 719–727. 8 indexed citations

14.

Kim, Hye Ryeon, Soomin Ahn, Hyunji Jo, et al.. (2021). The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. Frontiers in Oncology. 11. 792340–792340. 4 indexed citations

15.

Kim, Hong-Sik, Hana Kim, Ryul Kim, et al.. (2021). Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. Technology in Cancer Research & Treatment. 20. 2203804212–2203804212. 15 indexed citations

16.

Kim, Hye Ryeon & Won Mook Choi. (2017). Graphene modified copper current collector for enhanced electrochemical performance of Li-ion battery. Scripta Materialia. 146. 100–104. 45 indexed citations

17.

Kim, Hye Ryeon, Tae-Ung Yoon, Seung-Ik Kim, et al.. (2017). Beyond pristine MOFs: carbon dioxide capture by metal–organic frameworks (MOFs)-derived porous carbon materials. RSC Advances. 7(3). 1266–1270. 48 indexed citations

18.

Trung, Nguyễn Bảo, Tran Van Tam, Hye Ryeon Kim, et al.. (2014). Three-dimensional hollow balls of graphene–polyaniline hybrids for supercapacitor applications. Chemical Engineering Journal. 255. 89–96. 94 indexed citations

19.

Tam, Tran Van, Nguyễn Bảo Trung, Hye Ryeon Kim, Jin Suk Chung, & Won Mook Choi. (2014). One-pot synthesis of N-doped graphene quantum dots as a fluorescent sensing platform for Fe3+ ions detection. Sensors and Actuators B Chemical. 202. 568–573. 176 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact